Leukemia Research
Volume 25, Issue 12 , Pages 1067-1073 , December 2001

Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia

  • Je-Jung Lee

      Affiliations

    • Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-dong, Dong-ku, Kwangju 501-757, South Korea
    • ,
  • Ik-Joo Chung

      Affiliations

    • Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-dong, Dong-ku, Kwangju 501-757, South Korea
    • ,
  • Moo-Rim Park

      Affiliations

    • Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-dong, Dong-ku, Kwangju 501-757, South Korea
    • ,
  • Dong-Wook Ryang

      Affiliations

    • Department of Clinical Pathology, Chonnam National University Medical School, 8 Hak-dong, Dong-ku, Kwangju 501-757, South Korea
    • ,
  • Chang-Soo Park

      Affiliations

    • Department of Pathology, Chonnam National University Medical School, 8 Hak-dong, Dong-ku, Kwangju 501-757, South Korea
    • ,
  • Hyeoung-Joon Kim

      Affiliations

    • Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-dong, Dong-ku, Kwangju 501-757, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82-62-2206-572; fax: +82-62-2258-578

Received 10 May 2000 ,Accepted 30 April 2001.

References 

  1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995;1:27
  2. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New Engl. J. Med. 1995;333:1757
  3. Fox SB. Tumour angiogenesis and prognosis. Histopathology. 1997;30:294
  4. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb. Haemost. 1997;78:672
  5. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870
  6. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90:3167
  7. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717
  8. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer. 1999;81:1398
  9. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728
  10. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630
  11. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 1994;6:1567
  12. Bremner TA, Chatterjee D, Han Z, Tsan MF, Wyche JH. THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells. Leuk. Res. 1999;23:865
  13. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996;184:1075
  14. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood. 1997;90:1952
  15. Findley HW, Zhou M. The clinical significance of Fas expression in leukemia: questions and controversies. Leukemia. 1999;13:147
  16. Lickliter JD, Kratzke RA, Nguyen PL, Niehans GA, Miller JS. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Exp. Hematol. 1999;27:1519
  17. Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients. Blood. 1999;94:3135
  18. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957
  19. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88
  20. Lu C, Tanigawa N. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma. Cancer Res. 1997;57:221
  21. Volm M, Mattern J, Koomagi R. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas. Anticancer Res. 1999;19:1669
  22. Gonzalez-Palacios F, Sancho M, Martinez JC, Bellas C. Microvessel density, p53 overexpression, and apoptosis in invasive breast carcinoma. Mol. Pathol. 1997;50:304
  23. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 1995;55:5687
  24. Kuramoto K, Uesaka T, Kimura A, Kobayashi M, Watanabe H, Katoh O. ZK7, a novel zinc finger gene, is induced by vascular endothelial growth factor and inhibits apoptotic death in hematopoietic cells. Cancer Res. 2000;60:425
  25. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309
  26. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637
  27. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl. J. Med. 1999;341:1565
  28. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, et al. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug. Br. J. Haematol. 2000;108:391
  29. Thomas DA, Aguayo A, Estey E, Albitar M, O'Brien S, Giles FJ, et al. Thalidomide as anti-angiogenesis therapy in refractory or relapsed leukemias. Blood. 1999;94:507a
  30. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer. 1999;81:1398
  31. Maragoudakis ME, Peristeris P, Missirlis E, Aletras A, Andriopoulou P, Haralabopoulos G. Inhibition of angiogenesis by anthracyclines and titanocene dichloride. Ann. NY Acad. Sci. 1994;732:280
  32. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996;2:1843
  33. Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin. Cancer Res. 1998;4:1331
  34. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94:4143
  35. Clements MK, Jones CB, Cumming M, Daoud SS. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol. 1999;44:411
  36. Kini AR, Tallman MS, Lingen MW, Peterson LC. All-trans retinoic acid inhibits vascular endothelial growth factor-mediated angiogenesis in acute promyelocytic leukemia. Blood (Suppl. 1). 1999;94:75a
  37. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 1996;271:603
  38. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449
  39. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell. Biol. 1996;133:335
  40. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994;84:3603
  41. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol. 1997;9:139
  42. Dazzi F, Goldman J. Donor lymphocyte infusions. Curr. Opin. Hematol. 1999;6:394

PII: S0145-2126(01)00082-0

Leukemia Research
Volume 25, Issue 12 , Pages 1067-1073 , December 2001

Article Tools

* Image Usage & Resolution